Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Inspire Medical Systems Inc Stock Research

INSP

185.07USD+0.07(+0.04%)Market Closed
Watchlist

Market Summary

USD185.07+0.07
Market Closed
0.04%

INSP Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

INSP Stock Price

INSP RSI Chart

INSP Valuation

Market Cap

5.4B

Price/Earnings (Trailing)

-132.09

Price/Sales (Trailing)

10.31

EV/EBITDA

-132.99

Price/Free Cashflow

286.31

INSP Price/Sales (Trailing)

INSP Profitability

EBT Margin

-9.19%

Return on Equity

-8.64%

Return on Assets

-7.63%

Free Cashflow Yield

0.35%

INSP Fundamentals

INSP Revenue

Revenue (TTM)

526.1M

Revenue Y/Y

65.33%

Revenue Q/Q

18.14%

INSP Earnings

Earnings (TTM)

-41.1M

Earnings Y/Y

17.52%

Earnings Q/Q

22.51%

Price Action

52 Week Range

159.62330.00
(Low)(High)

Last 7 days

-12.3%

Last 30 days

-12.4%

Last 90 days

-41.3%

Trailing 12 Months

8.4%

INSP Financial Health

Current Ratio

8.91

INSP Investor Care

Shares Dilution (1Y)

6.27%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for INSP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-14
NELSON MARILYN C
acquired
1,880
0.94
2,000
-
2023-09-08
Herbert Timothy P.
sold
-
-
-47,992
ceo and president
2023-09-08
Herbert Timothy P.
gifted
-
-
-47,992
ceo and president
2023-08-28
Jandrich Steven
acquired
2,350
0.94
2,500
vp, human resources
2023-08-24
Herbert Timothy P.
gifted
-
-
-3,224
ceo and president
2023-08-23
Herbert Timothy P.
acquired
67,230
70.5459
953
ceo and president
2023-08-21
NELSON MARILYN C
acquired
1,880
0.94
2,000
-
2023-08-10
NELSON MARILYN C
acquired
1,880
0.94
2,000
-
2023-08-07
NELSON MARILYN C
acquired
1,880
0.94
2,000
-
2023-08-04
NELSON MARILYN C
acquired
1,880
0.94
2,000
-

1–10 of 50

Which funds bought or sold INSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
unchanged
-
4,067
14,578
-%
2023-09-20
BARCLAYS PLC
added
33.78
5,976,000
12,966,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
new
-
649
649
-%
2023-08-29
EFG Asset Management (Americas) Corp.
new
-
830,104
830,104
0.19%
2023-08-23
Stonebridge Capital Advisors LLC
unchanged
-
14,944
53,566
0.01%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
42.42
753,377
1,525,810
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.06
3,022,040
11,453,900
0.02%
2023-08-21
BOKF, NA
reduced
-2.54
803,906
3,089,600
0.06%
2023-08-21
OSAIC HOLDINGS, INC.
added
44.59
3,131,220
6,246,700
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
445,000
1,595,000
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying INSP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INSP
No. of Funds

Schedule 13G FIlings of Inspire Medical Systems

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.31%
2,978,391
SC 13G/A
Jan 31, 2023
blackrock inc.
7.4%
2,135,708
SC 13G/A
Nov 10, 2022
vanguard group inc
10.04%
2,899,902
SC 13G/A
Feb 03, 2022
blackrock inc.
6.7%
1,846,227
SC 13G/A
Jan 10, 2022
fmr llc
-
0
SC 13G/A
Feb 12, 2021
orbimed advisors llc
0.00%
0
SC 13G/A
Feb 10, 2021
vanguard group inc
8.92%
2,401,971
SC 13G
Feb 08, 2021
fmr llc
-
0
SC 13G/A
Feb 02, 2021
blackrock inc.
7.4%
1,993,714
SC 13G

Recent SEC filings of Inspire Medical Systems

View All Filings
Date Filed Form Type Document
Sep 18, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 28, 2023
4
Insider Trading
Aug 28, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 09, 2023
4
Insider Trading
Aug 08, 2023
4
Insider Trading
Aug 02, 2023
3
Insider Trading

Peers (Alternatives to Inspire Medical Systems)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
103.0B
6.7B
-0.75% 50.83%
72.29
15.46
11.75% -0.66%
77.8B
13.4B
6.45% 36.39%
85.31
5.81
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.2B
5.7B
-8.22% -17.24%
30.39
7.46
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
5.4B
526.1M
-12.44% 8.39%
-132.09
10.31
74.86% 6.49%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
2.3B
1.2B
-12.37% -42.27%
-97.15
1.82
-1.77% -138.27%
SMALL-CAP
2.1B
193.8M
-23.50% 16.21%
31.34
10.73
18.78% 144.88%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
47.7M
24.5M
-18.18% -19.57%
-3.81
1.95
-24.11% 3.57%
1.3M
6.2M
-81.65% 3.23%
-0.06
0.21
-28.21% -7.22%

Inspire Medical Systems News

Nasdaq
IWB's Underlying Holdings Could Mean 18% Gain Potential.
Nasdaq,
9 hours ago
Investor's Business Daily
StreetInsider.com

Returns for INSP

Cumulative Returns on INSP

33.0%


5-Year Cumulative Returns

13.1%


3-Year Cumulative Returns

Risks for INSP

What is the probability of a big loss on INSP?

96.5%


Probability that Inspire Medical Systems stock will be more than 20% underwater in next one year

73.5%


Probability that Inspire Medical Systems stock will be more than 30% underwater in next one year.

29.6%


Probability that Inspire Medical Systems stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Inspire Medical Systems was unfortunately bought at previous high price.

Drawdowns

Financials for Inspire Medical Systems

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue12.8%526,077,000466,371,000407,856,000348,354,000300,851,000262,424,000233,394,000201,005,000175,162,000134,386,000115,381,00096,278,00081,298,00087,147,00082,050,00071,703,00063,895,00056,801,00050,593,00043,991,00038,208,000
Gross Profit12.7%439,999,000390,372,000341,741,000293,235,000256,894,000225,122,000200,115,000171,721,000149,291,000114,079,00097,758,00081,577,00068,352,00073,061,00068,407,00059,106,00052,287,00046,185,00040,537,00035,247,00030,366,000
Operating Expenses11.8%493,625,000441,406,000389,333,000342,313,000298,574,000265,339,000239,965,000216,812,000194,478,000169,536,000153,966,000140,016,000125,550,000115,621,000103,304,00089,607,00078,786,00070,145,00060,915,00054,574,00048,693,000
  S&GA Expenses10.0%395,044,000359,112,000320,688,000284,622,000252,262,000224,273,000202,615,000182,471,000162,444,000140,728,000127,874,000117,442,000106,660,00099,947,00090,465,00078,383,00069,414,00061,884,00053,527,00050,208,00044,058,000
  R&D Expenses19.8%98,581,00082,294,00068,645,00057,691,00046,312,00041,066,00037,350,00034,341,00032,034,00028,808,00026,092,00022,574,00018,890,00015,674,00012,839,00011,224,0009,372,0008,261,0007,388,0006,918,0006,323,000
EBITDA100.0%--39,640,000-40,733,000-46,066,000-40,105,000-38,939,000-38,642,000-43,932,000-43,990,000-54,121,000-54,171,000-55,758,000-53,811,000-38,475,000-30,584,000------
EBITDA Margin100.0%--0.08-0.10-0.13-0.13-0.15-0.17-0.22-0.25-0.40-0.47-0.58-0.66-0.44-0.37------
Interest Expenses-43.0%656,0001,150,0001,677,0002,215,0002,096,0002,132,0002,128,0002,123,0002,119,0002,115,0002,117,0002,114,0002,110,0002,107,0002,119,0002,278,0002,429,0002,456,0003,304,0003,144,0002,892,000
Earnings Before Taxes6.1%-40,272,000-42,882,000-44,268,000-49,914,000-43,657,000-42,371,000-41,970,000-47,055,000-47,009,000-57,036,000-57,088,000-58,672,000-56,621,000-41,182,000-33,203,000-28,941,000-25,387,000-23,593,000-21,828,000-21,301,000-20,631,000
EBT Margin100.0%--0.09-0.11-0.14-0.15-0.16-0.18-0.23-0.27-0.42-0.49-0.61-0.70-0.47-0.40------
Net Income5.8%-41,073,000-43,611,000-44,881,000-50,422,000-43,922,000-42,520,000-42,042,000-47,135,000-47,173,000-57,174,000-57,203,000-58,799,000-56,661,000-41,222,000-33,243,000-28,941,000-25,387,000-23,593,000-21,828,000-21,302,000-20,631,000
Net Income Margin100.0%--0.09-0.11-0.14-0.15-0.16-0.18-0.23-0.27-0.43-0.50-0.61-0.70-0.47-0.41------
Free Cashflow-100.0%-11,339,0002,473,000-13,645,000-22,624,000-27,028,000-24,787,000-29,702,000-38,337,000-52,192,000-55,500,000-57,304,000-51,188,000-39,398,000-35,585,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets8.1%618572565528292290295279272273281272271166181183186190200131134
  Current Assets5.0%560534530496263262269255249261270267267155171170177189199130133
    Cash Equivalents5.6%46744244241818720321421017718219117921176.0023.0048.0051.0010297.0026.00122
  Inventory33.1%21.0016.0012.0015.0022.0022.0017.0016.0013.0011.008.009.0010.007.006.005.004.003.003.003.004.00
  Net PPE20.5%25.0021.0017.0014.0011.009.008.008.007.007.005.004.003.003.003.003.002.001.001.001.001.00
Liabilities32.3%89.0067.0069.0057.0065.0065.0066.0059.0052.0050.0051.0043.0038.0038.0041.0037.0033.0032.0036.00--
  Current Liabilities11.4%67.0060.0061.0049.0047.0043.0041.0034.0024.0019.0021.0018.0013.0014.0017.0013.009.008.0011.008.009.00
Shareholder's Equity4.9%52950549647022722522922022022323022923412714014615215716498.00103
  Retained Earnings-3.5%-351-339-324-327-310-296-279-277-266-253-237-229-219-196-180-171-162-155-146-142-137
  Additional Paid-In Capital4.3%881844820798538521508497487477467459453323320317315313311240240
Accumulated Depreciation----------------1.001.001.001.001.001.00
Shares Outstanding0.6%29.0029.0029.0029.0028.0028.0027.0027.0027.0027.0027.0027.0026.0024.0024.0024.0024.0023.0015.0012.0014.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations48.1%34,01922,97311,569-6,966-18,306-22,466-20,119-24,963-33,534-48,671-53,045-55,011-49,046-36,679-32,846-29,359-29,968-23,218-18,694-19,382-18,956
  Share Based Compensation14.7%69,38260,47451,97043,99936,22029,90226,17823,00219,50316,06512,81710,8569,0697,5556,1974,8273,6752,5551,219750459
Cashflow From Investing74.5%-5,570-21,884-19,596-17,17916,73228,99529,13941,068-15,01018,06586,62755,23980,6677,726-43,559-19,945-111,478-67,858-83,389-89,459-2,351
Cashflow From Financing6.0%251,979237,664235,077231,86411,58214,44214,94815,39313,862136,828134,065130,441128,3213,1171,96470,97770,831181,832190,383120,613120,653

INSP Income Statement

2023-06-30
Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 151,092$ 91,386$ 278,989$ 160,768
Cost of goods sold24,25214,17344,14024,177
Gross profit126,84077,213234,849136,591
Operating expenses:    
Research and development30,82114,53456,34026,404
Selling, general and administrative112,61876,686214,606140,250
Total operating expenses143,43991,220270,946166,654
Operating loss(16,599)(14,007)(36,097)(30,063)
Other expense (income):    
Interest and dividend income(4,922)(297)(9,195)(331)
Interest expense049401,021
Other expense, net6114444189
Total other (income) expense(4,861)341(9,151)879
Loss before income taxes(11,738)(14,348)(26,946)(30,942)
Income taxes214142430242
Net loss(11,952)(14,490)(27,376)(31,184)
Other comprehensive loss:    
Foreign currency translation gain724217742
Unrealized (loss) gain on investments(1)(45)12(188)
Total comprehensive loss$ (11,881)$ (14,493)$ (27,187)$ (31,330)
Net loss per share, basic (in dollars per share)$ (0.41)$ (0.53)$ (0.94)$ (1.13)
Net loss per share, diluted (in dollars per share)$ (0.41)$ (0.53)$ (0.94)$ (1.13)
Weighted average common shares used to compute net loss per share, basic (in shares)29,229,92227,594,87429,160,32327,556,286
Weighted average common shares used to compute net loss per share, diluted (in shares)29,229,92227,594,87429,160,32327,556,286

INSP Balance Sheet

2023-06-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 467,051$ 441,592
Investments, short-term09,821
Accounts receivable, net of allowance for credit losses of $917 and $36, respectively63,50061,228
Inventories, net20,84011,886
Prepaid expenses and other current assets8,6855,505
Total current assets560,076530,032
Property and equipment, net25,21717,249
Operating lease right-of-use assets21,3686,880
Other non-current assets11,58510,715
Total assets618,246564,876
Current liabilities:  
Accounts payable39,96126,847
Accrued expenses26,72634,339
Total current liabilities66,68761,186
Operating lease liabilities, non-current portion22,0547,536
Other non-current liabilities146146
Total liabilities88,88768,868
Stockholders' equity:  
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding00
Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 29,326,179 and 29,008,368 issued and outstanding at June 30, 2023 and December 31, 2022, respectively2929
Additional paid-in capital880,873820,335
Accumulated other comprehensive income (loss)103(86)
Accumulated deficit(351,646)(324,270)
Total stockholders' equity529,359496,008
Total liabilities and stockholders' equity$ 618,246$ 564,876
Timothy P. Herbert
480
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.